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ABSTRACT 
This study investigates encapsulation efficiency of model drug, encapsulated by 
magnetic PLGA (poly D,L-lactic-co-glycolic acid) nanoparticles (NPs). This is the 
following part of our preceding paper, which is referred in this paper as Part I. Magnetic 
nanoparticles and model drug human serum albumin (HSA) loaded PLGA NPs were 
prepared by double emulsion solvent evaporation method. Among five important process 
variables, concentration of PLGA and concentration of HSA in the inner aqueous phase 
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along with their cross-effect had the strongest influence on the encapsulation efficiency. 
Encapsulation efficiency of nanoparticles ranged from 18 to 97% depending on the 
process conditions. Higher encapsulation efficiencies can be achieved by using low HSA 
and high PLGA concentrations. The optimization process, carried out by exact 
mathematical tools using GAMSTM/MINOS software makes it easier to find out optimum 
process conditions to achieve comparatively high encapsulation efficiency (e.g. 92.3%) 
for relatively small sized PLGA NPs (e.g. 155 nm). 
Keywords: encapsulation efficiency; poly(D,L-lactic-co-glycolic) acid; human serum 
albumin; magnetite nanoparticles; experimental design. 
___________________________________ 
* Correspondance: Quazi T. H. Shubhra; email: shubhro.du@gmail.com;  
Fax:+36-88624038 ; Tel : +36204843689. 
 
INTRODUCTION  
Nanoparticles have been extensively investigated in biomedical and 
biotechnological areas, especially in drug delivery systems for drug targeting because of 
their small particle size (ranging from 10 to 1000 nm) which is one of the most important 
properties for intravenous injection formulas (Mainardes et al. 2005; Allemann et al. 
1998; Jeon et al. 2000; Soppimath et al. 2001). Until now, a large number of different 
polymers have been investigated for formulating biodegradable nanoparticles. Among 
them poly(L-lactic-acid) (PLA) and its copolymers with glycolic acid called poly(D,L-
lactic-co-glycolic acid) (PLGA) have gained popularity as vehicles for drug delivery 
systems (Uhrich et al. 1999; Vert et al. 1998; Park et al. 1995; Jain et al. 2000).  
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Drug loaded PLGA nanoparticles have been extensively studied in recent years 
due to their excellent drug loading capacity and biocompatibility. Many PLGA-based 
nanoformulations have reached different stages of preclinical development, although they 
still present distinct challenges for researchers. The lactide/glycolide polymers chains are 
cleaved by hydrolysis into natural metabolites (lactic and glycolic acids), which are 
eliminated from the body by the citric acid cycle. PLGA provides a wide range of 
degradation rates, from months to years, depending on its composition and molecular 
weight (Mainardes et al. 2005; Burkersroda et al. 2002; Peppas, 1995 Panyam et al. 2003) 
and was selected in this study. 
Nanocapsules containing magnetic nanoparticles offer several advantages over 
conventional systems; most important one is targeted delivery of medicaments. Selection 
of magnetic nanoparticles for this research was a challenging task because of toxic 
character of some magnetic nanoparticles. Most of the research on magnetic 
nanoparticles for clinical applications has focused on iron oxide nanoparticles such as 
magnetite (Fe3O4) or maghemite (γ-Fe2O3) dDue to their biological compatibility and 
FDA approval for clinical usage (Weissleder et al. 1989; Ibrahim et al. 1983; Muller et al. 
1996; Andujar et al. 2012), magnetite was used in this study. In this study, oleic acid-
coated magnetite (Fe3O4) nanoparticles were selected, because they are well dispersible 
in organic media.  
Human serum albumin (HSA) can be used to model the encapsulation behavior of 
a protein-type drug. It is a monomeric multi-domain macromolecule, The model drug 
used was HSA which is the most abundant plasma protein in the human body with a 
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plasma concentration of 0.6 mM (Yang et al. 2007). HSA consists of 585 amino acids 
that form three structurally similar α-helical domains. 
Polyvinyl alcohol (PVA) was used as is a very effective emulsifier for PLGA. It 
which helps to form particles of relatively small size and uniform size distribution 
(Scholes et al. 1993; Zambaux et al. 1998). Organic solvent used was dichloromethane 
(DCM). has the ability to dissolve a wide range of organic compounds including PLGA. 
DCM is volatile at room temperature and evaporates very quickly. In manufacturing the 
nanoparticles, it can be removed completely by evaporation from a mixture by 
mechanical stirring. 
W/O/W (i.e. water-in-oil-in-water) type double emulsion-solvent evaporation 
method is one of the most commonly used techniques for preparing PLGA nanoparticles 
(Dillen et al. 2006; Ubrich et al. 2004; Song et al. 2008). Therefore, this method was used 
to co-encapsulate HSA and superparamagnetic nanoparticles. Although 
nanoprecipitation, phase separation (coacervation), etc. can also be considered for 
formulation of drug loaded PLGA particles, double emulsion method has attracted us 
because of its ease and simplicity to carry out. Although single emulsion method is 
simpler than double emulsion method, for studying three phase systems, double emulsion 
method had to be applied because of their compartmentalized internal structure. The 
internal aqueous phase contained the model drug to be encapsulated, the intermediate 
organic phase served as solvent for the polymer matrix material, while the external 
aqueous phase was applied as the dispersant for the organic polymer solution 
(intermediate phase). The main benefit of double emulsion method is the high 
encapsulation efficiency of protein compounds in organic soluble polymers. In the 
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production of drug-loaded nanoparticles, encapsulation efficiency of the expensive drug 
ingredient(s) is one of the most important factors. Depending on the desired 
administration way, beside the encapsulation efficiency, the size of the carriers should 
also be optimized. If nanoparticles are intended e.g. for injection formulas, their size 
should preferably be lower than 220 nm, since they can be sterilized by ultra-filtration 
through a membrane of 220 nm cut-off (Feczko et al. 2011). 
Thus, the goal of this study was to investigate the encapsulation efficiencies of 
prepared nanoparticles. Due to experimental design (made by STATISTICA® software), 
it was possible to explore precisely the influence of different parameters and their 
combined influences on encapsulation efficiency. GAMS™/MINOS software was used 
for optimization which gave precise result. Earlier no comprehensive studies were carried 
out on the particular effect of the studied five parameters and process conditions on the 
PLGA nanoparticles and no research was carried out on co-encapsulation of HSA and 
oleic acid coated magnetite by PLGA (the size of PLGA NPs is discussed in part I) which 
for sure makes this novel study not only interesting but also creates scope for further 
research and innovation. The outcome of this study will provide the ideal combination of 
variables to get comparatively high percentage of model drug loading for smallest 
possible size of PLGA nanoparticles which will be exploited with the real drug for further 
innovation in the field of targeted drug delivery. 
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MATERIALS AND METHODS 
Materials 
PLGA (50:50, Mw = 8000, Resomer
® RG 502H) with free carboxyl end groups 
was supplied by Boehringer Ingelheim, Germany. HSA solution was obtained from 
Trigon Biotechnological Ltd., Hungary. The concentration of bulk HSA solution was 
36.87 g/L. Dichloromethane (DCM) was purchased from Spektrum-3D, Hungary. PVA 
(Mw = 30,000–70,000) and phosphate-buffered saline (PBS, pH 7.4) were products of 
Sigma-Aldrich. Micro BCA (bicinchoninic acid) protein assay kit was purchased from 
Pierce Biotechnology, Inc. 
 
Synthesis of oleic acid-coated superparamagnetic iron oxide nanoparticles 
Neat superparamagnetic iron oxide nanoparticles were prepared by co-
precipitation of Fe(II) and Fe(III) chlorides in aqueous ammonia solution by modification 
of an earlier published method (Horak et al. 2003). The detailed process was described in 
the preceding paper (Part I). The size of magnetite obtained was 10 ± 5 nm. 
Magnetite is coated with oleic acid to prevent agglomeration. Magnetic 
nanoparticles have large surface area to volume ratio. So, they have a tendency to 
agglomerate in order to minimize their surface energy which can be successfully 
prevented using oleic acid coating. Oleic acid is a naturally occurring fatty acid and have 
been using in pharmaceutical industries because of its low cost and toxicity. Oleic acid 
coating will prevent the chemical or mechanical interaction between the drug/model drug 
and the magnetite inside matrix type drug carriers. 
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Preparation of PLGA nanoparticles 
PLGA nanoparticles were prepared by using double emulsion-solvent evaporation 
method (Feczko et al. 2008; Panyam et al. 2003). The detailed process was described in 
Part I. 
Determination of encapsulation efficiency 
Encapsulation efficiency of model protein drug was determined by micro BCA 
assay. The amount of HSA model protein drug encapsulated into the PLGA nanoparticles 
was determined by analyzing the protein content in the supernatant (i.e. the not 
encapsulated fraction of the protein introduced). The resultant encapsulation efficiency 
(EEHSA) was defined as the percentage of HSA model protein encapsulated into the 
PLGA nanoparticles relative to the total amount of HSA dissolved in the inner aqueous 
phase according to equation (1): 
%100
int
×=
HSA
HSA
HSA
m
m
EE
encaps        (1) 
In micro BCA assay, peptide bonds in protein reduce cupric (Cu2+) to cuprous 
ions (Cu+). Two molecules of bicinchoninic acid chelate with each Cu+ ion, forming a 
purple-colored product that strongly absorbs light at a wavelength of 562 nm and is 
analyzed spectrophotometrically (Nielsen, 2010). The amount of Cu2+ reduced is 
proportional to the amount of protein present in the solution. 
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Experimental design 
To elucidate the effect of process conditions on the mean particle size and 
encapsulation efficiency, and to decrease the number of the studied parameter 
combinations and thus the number of experiments, a 3(p-1) type fractional factorial 
experimental design was carried out using STATISTICA® (version 10.0, StatSoft Inc., 
USA) software, where “p” is the number of factors. The obtained experimental data were 
evaluated by statistical analysis, similarly to the method described by Feczkó et al. 
(Feczko et al. 2011) for production of PLGA nanoparticles containing bovine serum 
albumin (BSA), and by Biró et al. (Biro et al. 2009) for chitosan microparticles. 
Five process variables (also called as “factors”, denoted by F1–F5) summarized in 
Part I were examined as main influencing parameters for studying both the mean particle 
size and the encapsulation efficiency. These variables were: XFe3O4 (% wt/wt) - the 
amount of iron oxide in the organic phase relative to the weight of PLGA (factor F1), 
XPLGA (% wt/vol) - the concentration of PLGA in the organic phase (factor F2), XHSA (% 
wt/vol) - the concentration of HSA in the inner aqueous phase (factor F3), XVOLR 
(vol/vol) - the volume ratio of the outer aqueous phase related to the volume of organic 
phase (factor F4), and Xtime (min) - the duration of the ultrasonic treatment in minutes 
during the second emulsification (factor F5). 
To elucidate the effects of these five process variables on encapsulation 
efficiency, the same series of experiments were used as was done in studying the mean 
particle size discussed in Part I. For this, altogether 3(5-1) = 81 experiments were needed. 
Additionally, 9 repetitions of experiments were also carried out to estimate the pure error. 
According to our experimental design 3 different levels of each variable (the lowest, 
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highest and central values of their studied intervals) were tested. The main advantage of 
experimental design is the great reduction of experimental work without remarkable loss 
of the gained information. It means that instead of 35 = 243 experiments needed without 
experimental design, only 34 = 81 experiments (i.e. one third of the original ones) had to 
be carried out with experimental design, excluding repetitions. The experimental program 
determined by the Industrial Statistics/DOE part of software package STATISTICA® was 
shown in the table of the Appendix “A” in Part 1, together with the measured values of 
mean particle sizes and encapsulation efficiencies obtained for each experiment.  
Optimization of the result  
From economic point of view, the efficiency of encapsulation is extremely 
important, especially when the active agent is very expensive. In certain applications, 
such as production of injectable drug formulations, the smallest possible particle size 
with highest possible encapsulation efficiency must be achieved which obviously 
depends on the process variables. Although encapsulation efficiency is generally higher 
for larger nanoparticles, they are detected and eliminated by macrophages easily and on 
the other hand, their sterilization after production is difficult. Due to the high number of 
variables, it was necessary to determine the optimum process conditions mathematically 
to achieve higher model drug loading with the smallest PLGA capsules. For this purpose 
the GAMS™/MINOS Large Scale Nonlinear Solver for Windows Ver. 5.51 (System 
Optimisation Laboratory, Stanford University) software was applied which suggested the 
optimum process conditions by precise mathematical tools. 
RESULTS AND DISCUSSION  
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As a result of the statistical analysis carried out on the measured encapsulation 
efficiency data, the influences of the studied process variables were characterized by the 
ANOVA table (see Table 1) and Pareto chart of the standardized effects. From Table 1 it 
is seen that linear (L) and quadratic (Q) effects of PLGA concentration (factor F2), the 
linear effect of HSA concentration (factor F3), and the cross-effect (linear-linear 
interaction) of these two factors (F2*F3) had the strongest influences. The quadratic (Q) 
effect of the weight ratio of magnetite/PLGA (factor F1), and the linear-linear 
interactions of the PLGA concentration and the volume ratio of external aqueous and 
intermediate organic phases (F2*F4), and that of the HSA concentration and volume ratio 
(F3*F4) also have significant effects, respectively. From ANOVA table it is seen that all 
of these effects are statistically significant, since the related p values are much below the 
commonly accepted p=0.05 criterion. Table 1 also shows that the mean square of 
residuals (MS) was 84.425, i.e. the mean deviation between the measured and estimated 
encapsulation efficiencies is 19.9425.84 ±= %, which can be considered as an 
acceptable deviation. The histogram of residuals (not presented here) showed almost 
normal distribution, therefore the estimation made by the multivariable regression applied 
in the STATISTICA® software was acceptable. The pure error of experimental data 
determined from the mean square of the deviations of the encapsulation efficiencies 
measured in 9 repeated runs at the central values of all variables was +5.8%, which is 
regarded as good accuracy.   
Table 1. 
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The Pareto chart (Fig. 1) shows that the encapsulation efficiency was affected 
mostly by: PLGA concentration in the intermediate organic phase (F2 - linear (L) and 
quadratic (Q) effects), HSA concentration in the inner aqueous phase (F3 - linear effect 
(L)), and linear-linear interaction of these two factors. The iron oxide/PLGA weight ratio 
(F1) had lower and quadratic effect. Although the linear-linear interaction of volume ratio 
(F4) with PLGA concentration and also with HSA concentration was significant, they 
had minor effects. Among the studied five variables, the duration of sonication had no 
direct effect at all on the encapsulation efficiency. The explanation is given in section 3.5. 
Fig. 1. 
As a result of the statistical analysis, a regression equation was obtained to 
describe the dependence of the encapsulation efficiency EEHSA on the studied process 
variables: 
HSAPLGAOFeHSAPLGAPLGAHSA XXXXXXEE ⋅⋅+⋅−⋅−⋅−⋅= 0632.40075.04573.210993.43189.25
2
43
2
              2188.72XX3810.1XX1217.1 VOLRHSAVOLRPLGA +⋅⋅+⋅⋅−         (2) 
These effects are demonstrated by the diagrams in Fig. 2-5 and discussed in details 
below. 
Effect of PLGA and HSA concentrations 
Increased PLGA concentrations can generally be beneficial to achieve higher 
encapsulation efficiency, but this effect can be diminished under certain conditions due to 
the influence of other process variables. Among them, the most important one is the 
concentration of HSA in the inner aqueous phase. Fig. 2(a) clearly shows this effect at 
Page 11 of 42
URL: http://mc.manuscriptcentral.com/tmnc  Email: microencapsulation@hotmail.co.uk
Journal of Microencapsulation
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review Only
 12
fixed magnetite/PLGA mass ratio (3.0% wt/wt), volume ratio of W2 and O phases (4.0 
vol/vol) and sonication time (3.0 min). It is seen that the encapsulation efficiency varies 
non-linearly with the change of PLGA concentration: the increase in the encapsulation 
efficiency is most rapid at the highest model drug concentration (XHSA=3.7% wt/vol), 
which can grow from 45.1 to 91.1% when XPLGA changes from 1.0 to 4.0% (wt/vol). The 
increment of encapsulation efficiency is gradually decreasing with the increase in PLGA 
concentration for medium and low HSA concentration, i.e. rapid growth is seen around 
XPLGA=1.0% (wt/vol), which slows down at higher PLGA concentrations, e.g. above 
2.5% (wt/vol). However, at low HSA concentration (XHSA=0.7% wt/vol) the effect of 
PLGA is much more moderate, starting from an encapsulation efficiency of about 80.1%, 
reaching to a maximum of about 90.1%.  
Due to the cross-effect (interaction) between the PLGA and HSA, the influence of 
HSA concentration depends on the actual level of PLGA concentration. As is seen on 
Fig. 2(a), if lowest amount of PLGA is used (XPLGA=1% wt/vol) in the intermediate 
organic phase, the increase of XHSA causes a reduction in the encapsulation efficiency 
from the mentioned 80.1% to about 45.1%. However, if PLGA concentration in the 
organic phase is high, e.g. its maximal value of 4.0% (wt/vol), the increase of HSA 
concentration to its maximal value (XHSA=3.7% wt/vol) results in a slight increase in the 
achievable encapsulation efficiency from about 90.1 to 91.1%. The explanation of this 
interaction lies in the fact that greater amount of PLGA matrix material can absorb more 
model protein drug. If the presence of PLGA is not sufficient, relatively smaller 
proportion of the total amount of HSA can be captured in the particles resulting lower 
encapsulation efficiency. 
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The literature data support our findings on the effect of PLGA, because it is 
known that the efficiency of encapsulation generally increases with the increase in the 
relative amount of the polymer matrices. Another effect may be that at certain conditions, 
particle size can also increase with the polymer concentration (Coimbra et al. 2008) and 
the encapsulated drug content is known to increase with the increase in particle size 
(Gorner et al. 1999; Budhian et al. 2007).  
Fig. 2 a,b,c,d. 
Further explanation can be that with the increase in the concentration of polymer 
in the organic phase, the viscosity of the organic phase increases. The more viscous 
organic phase provides higher mass transfer resistance (Galindo-Rodriguez et al. 2004) 
and prevents protein diffusion towards the external phase, which in turns results in higher 
encapsulation efficiency. Increasing the PLGA concentration at a given HSA 
concentration will decrease the HSA/PLGA ratio in the droplets of the organic phase. 
This also may reduce the possibility of its escaping from these droplets. Devi Kusum et 
al. found that if drug (Acyclovir):polymer (PLGA) ratio increases from 1:1 to 1:2, 
particle size increases significantly and drug entrapment also increases (Kusum et al. 
2009). 
As for the effect of HSA concentration, it is seen that the increase in the HSA 
concentration decreases the encapsulation efficiency. The high model drug loadings 
typically result in lower encapsulation efficiencies due to high concentration gradient 
causing the drug to diffuse out of the droplets (Maravajhala et al. 2009). So, the lower 
encapsulation efficiencies obtained with higher HSA concentrations could be explained 
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by the higher protein loss by diffusion towards the external aqueous phase. During the 
solidification of droplets, the quantity of solvent in the dispersed phase decreases and the 
drug will show the tendency to be expelled from the dispersed phase (Li et al. 2008). 
Some researchers also pointed out that microspheres with high drug loadings are more 
porous and have rather irregular shapes; highly porous surface is responsible for the rapid 
loss of drug (Li et al. 2008). This can be also a reason for the loss of HSA from PLGA 
nanospheres. Too high drug loading increases the risk of drug leakage due to the limited 
space inside the nanospheres and the shrinkage of the nanospheres during its 
solidification. Pamujula et al. (Pamujula et al. 2004) studied amifostine drug-loaded 
PLGA microcapsules. It was found that the efficiency of encapsulation decreased with an 
increase in drug loading which complies with our result. 
The HSA/PLGA ratio is also an important parameter compared to the protein 
concentration in the inner aqueous phase. Insufficient concentration of the PLGA can 
result in more non-encapsulated HSA. In our previous studies, it was found in this respect 
that if the initial protein concentration is not higher than 10% (wt/vol) of the initial PLGA 
amount, more than 90% of protein can be encapsulated by using a suitable emulsifier 
(Feczko et al. 2011).  
Effect of the magnetite/PLGA mass ratio 
As is seen from the very small coefficient of XFe3O4 in Eqn. 2, and also from Fig. 
2(b)3, the presence of magnetite has only slight influence on the encapsulation of HSA 
into the PLGA nanoparticles. With the increase in magnetite/PLGA ratio from 1.0 to 
20.0% (wt/wt), the predicted encapsulation efficiency shows slight reduction only from 
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EEHSA=65.2 to 62.2% at low (1.0% wt/vol) PLGA concentration, and from EEHSA=90.6 
to 87.6% at the highest studied polymer content (XPLGA=4.0% wt/vol), respectively.   
Fig. 3. 
This decrease may be due to the possibility that with the higher Fe3O4/PLGA 
mass ratio, more magnetite particles can escape from the model drug loaded PLGA 
nanoparticles and can be dispersed into the outer aqueous phase. In this process some 
model protein drug may be adsorbed on the surface of the escaped magnetite 
nanoparticles, which will r sult in some protein loss and lower encapsulation efficiency. 
The interaction of the PLGA concentration and the volume ratio  
It can be seen from the Pareto chart (Fig.1) and Eqn. 2 that the volume ratio of the 
external aqueous and the intermediate organic phases (XVOLR) does not have its own 
independent effect on the encapsulation efficiency, because it interacts with two other 
process variables. Namely, the effect of the volume ratio can be influenced by both of the 
PLGA and HSA concentrations, and vice versa. Fig. 2(c)4 shows certain cross-effect of 
the volume ratio and PLGA concentration. 
Fig. 4. 
As was seen earlier, an increase in PLGA concentration results in a rapid increase 
of encapsulation efficiency, especially in the lower region of the studied interval. The 
change of volume ratio of the W2/O phases can slightly modify the achievable degree of 
encapsulation in a considerable range of PLGA concentrations. At the lower end of 
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polymer concentration, i.e. at around XPLGA=1.0% (wt/vol), the increase of volume ratio 
from XVOLR=2.0 to 6.0 (vol/vol) causes a rise in the encapsulation efficiency from 
EEHSA=61.9 to 68.4% at fixed values of three other variables indicated on Fig. 2(c)4. At 
the higher end of the PLGA concentration range (XPLGA=4.0% wt/vol), the effect of the 
volume ratio of phases W2/O is opposite: the increase of volume ratio from 2.0 to 6.0 
(vol/vol) results in the decrease of encapsulation efficiency from EEHSA=94.0 to 87.1%. 
This phenomenon may be explained by a general principle that governs the size of 
nanodroplets during shearing the given three-phase system by an external energy source. 
It is known from the literature that the size of droplets is inversely proportional to the 
magnitude of shear stresses (Budhian et al. 2007)]. Any change in process variables that 
reduces these shear stresses will increase the nanodroplet size. In our experiments the 
introduced ultrasonic energy was constant for different volume ratios. Therefore the 
higher the volume ratio, the higher the liquid volume is, which in turn reduces the 
available energy per unit volume, i.e. less energy density, resulting in weaker 
emulsification. Weaker emulsification leads to the production of larger particles if all the 
other variables are fixed. From larger droplets (or particles) less protein can escape to the 
external aqueous phase.  
On the other hand, at higher energy density during shearing the intermediate 
organic phase into droplets (containing the already dispersed inner aqueous phase, HSA 
solution) increases the probability that the tiny droplets of the HSA solution can get into 
direct contact with the outer aqueous phase, which allows intermingling and their fusion, 
thus causing protein loss and lower encapsulation efficiencies. This could be a reasonable 
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explanation of the increase of encapsulation efficiency with increasing volume ratio at the 
lower end of PLGA concentration. The controversial effect at high PLGA concentration 
is not well understood yet, but may be the consequence of higher PLGA concentration 
that increases the viscosity of the intermediate organic phase which may protect the inner 
aqueous phase from the direct contact with the external aqueous phase during shearing, or 
at least can diminish the fusion of the droplets of the inner aqueous phase with the outer 
continuous aqueous phase. The increase of encapsulation efficiency with decreasing 
volume ratio at higher PLGA content can be caused by reduced HSA extraction from 
high viscous organic phase by the relatively small amount of the external aqueous phase.  
It should be noted that the cross-effect between the PLGA concentration and 
volume ratio, and their combined influence on the encapsulation efficiency is statistically 
significant and thus has to be considered, but this is not the most important effect as a 
whole.   
The interaction of HSA concentration and volume ratio 
The interaction between the HSA concentration in the inner aqueous solution and 
the W2/O phases volume ratio is clearly seen in Fig. 2(d)5, where the magnetite to PLGA 
ratio, the PLGA concentration in the organic phase, and the time of sonication are fixed 
(XFe3O4=3.0% wt/wt, XPLGA=2.5% wt/vol, and Xtime=3.0 min). Namely, at low volume 
ratio (XVOLR=2.0 vol/vol), the decrease of HSA concentration from 3.7 to 0.7% (wt/vol) 
results in significant increase in the encapsulation efficiency (from 72.7 to 98.2%), while 
for same change in HSA at high volume ratio (XVOLR=6.0 vol/vol) the encapsulation 
efficiency changes from 81.9 to 90.9%. On the other hand, the effect of volume ratio at 
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high HSA concentration (XHSA=3.7% wt/vol) is also significant: by increasing the 
volume ratio from 2.0 to 6.0 vol/vol, the efficiency of encapsulation grows from 72.7 to 
81.9%. At low HSA concentration (XHSA=0.737% wt/vol), the tendency is just opposite: 
the same increase of the volume ratio leads to the decrease of the encapsulation efficiency 
from 98.2 to 90.9%.  The beneficial effect of the increase in volume ratio at high HSA 
concentration has already been explained above by the lower energy density and small 
shear stress, which leads to larger particles and minimizes protein loss. The decrease of 
encapsulation efficiency with increasing volume ratio at lower HSA concentration seems 
to be contradictory for the first sight, but it becomes understandable by the fact that more 
external water phase can extract more HSA from the droplets of the first W1/O emulsion 
during shearing them in the external continuous W2 phase. 
Fig. 5. 
Effect of sonication duration on the second emulsification  
It has been shown in Part I that at given values of other influencing variables the 
increase in sonication time has decreased the achievable mean particle size of the 
HSA/magnetite loaded nanoparticles significantly. In spite of this fact, the statistical 
analysis of the data obtained for entrapping of HSA does not show any significant direct 
effect of sonication time on the degree of encapsulation. This was especially interesting 
because it is known from other studies that particle size greatly influences the 
encapsulation efficiency, which usually increases with increasing particle size and vice 
versa. Several authors have pointed out for drug-loaded particles that in general the larger 
the particle size, the higher the encapsulation efficiency for drugs (Feng et al. 2001; Zhao 
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et al. 2007).  This is the reason why the encapsulation efficiency of nanospheres is 
usually lower than that of microspheres (Wang et al. 1996; Sato et al. 1996). The lower 
encapsulation efficiencies obtained with the smaller particles was explained by the larger 
surface area of smaller droplets. Hence, during the emulsification step, a more direct 
contact between internal and external phases occurred which resulted in higher loss of 
model drug (HSA) by diffusion to the external medium (Dey et al. 2009). Inversely, for 
larger droplets, the surface area per unit mass is comparatively smaller. So, the loss of 
model drug will be lower and thus higher encapsulation efficiencies are obtained. Such an 
explanation agrees with the results of Gorner and Feng (Gorner et al. 1999; Feng et al. 
2001). Moreover, an increase in particle size increases the length of diffusional pathways 
into the aqueous phase, thereby reducing the drug loss through diffusion and increasing 
the drug content (Budhian et al. 2007). Dey et al. have also found that encapsulation 
efficiency of nanoparticles increased from about 68 to 86% with the increment of their 
mean diameter from 64 nm to 255 nm (Dey et al. 2009). Similar results were found by 
Gorner et al. (Gorner et al. 1999) where drug encapsulation efficiency grew with the 
increase in the particle size from about 19% for small particles to about 34% for medium 
and up to about 57% for large nanospheres which also complies with our earlier result 
(Feczko et al. 2011) and strongly supports our present finding. 
Although the mean particle size was influenced by the duration of second 
sonication (see Part I), no direct relation was obtained between the latter and the 
encapsulation efficiency. The explanation of this apparent contradiction can be that, 
besides the duration of ultrasonic treatment, both particle size and the encapsulation 
efficiency were strongly influenced by other process variables as is seen in Fig. 63a and 
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63b. It is clearly seen from these plots that along the increasing sonication time both the 
mean particle size and the encapsulation efficiency are highly scattered due to the 
variation of the other influencing parameters at given sonication time. Therefore, the real 
effect of sonication time and particle size can only be explored by statistical analysis of 
the data, suitable to study the particular effects of different process variables. The effect 
of mean particle size on encapsulation efficiency can be explored by the optimization of 
the results also at various constraints, which will be discussed in details in section 3.8.  
Fig. 36. 
From Fig. 63a and 63b it is obvious that, depending on other process variables, at 
given sonication time, quite different particle sizes can be produced (Fig. 63a), and even 
for a given mean particle size quite different encapsulation efficiencies were achieved 
(Fig. 63b). However, process variables are optimized (section 3.8) in respect to get 
various predefined mean particle sizes with maximal encapsulation efficiency utilizing 
the descriptive model equations.  
HSA loading in the particles   
The concentration of the active ingredient in the nanoparticles is also of primary 
importance in respect of their applications as drug preparations. Therefore the model drug 
loading (i.e. HSA concentration (% wt/vol) in the total mass of particles) can be 
calculated as: 
%100
43
×
++
=
encapsencaps
encaps
encaps
HSAOFePLGA
HSA
HSA
mmm
m
X              (3a) 
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In the planned application studies, the concentration of superparamagnetic 
magnetite NPs in the capsules of final product will be kept at relatively low level (few 
percent only). Thus for the sake of simplicity, the mass of magnetite in Eqn. 3 can be 
neglected. 
Since the value of any protein type drug ingredient is several order of magnitude 
higher than the price of iron oxide, the purpose of our study was to determine the 
influence of process variables on the encapsulation of the model drug. The degree of iron 
oxide encapsulation was therefore of secondary importance, and served only to ensure a 
suitable magnetic behavior of particles after their administration in living organism. On 
the other hand, to minimize any side effects, as small amount of iron oxide nanoparticles 
should be present in the final drug formulation as possible, which can be realized at 
relatively low magnetite/PLGA mass ratios. Iron oxide content was measured by 
detection of iron (Fe3+) complex using a colorimetric method that is based on a prussian 
blue reaction and analyzed by UV/vis spectrophotometer. According to our observations, 
the encapsulation efficiency of magnetic nanoparticles was close to 100 %, when the 
initial iron oxide was 1 % (wt/wt) related to the PLGA mass; viz. no detectable amount of 
non-encapsulated iron oxide remained in the supernatant after the separation of PLGA 
nanoparticles. It should be noticed that at higher magnetite/PLGA ratio the degree of 
encapsulation could not quantitatively be determined because of the difficulty of 
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separation of the encapsulated and non-encapsulated magnetic nanoparticles. The 
dependence of magnetic properties of the final product as a function of the encapsulated 
iron oxide nanoparticles will be the subject of further studies. 
Optimization of the process variables 
In the production of drug-loaded NPs, the general goal is to achieve suitable small 
particle size and at the same time, high encapsulation efficiency. From the results of our 
study it was revealed that simultaneous achievement of the two requirements is not an 
easy task because the eff cts of some process variables may be opposite (or at least 
competitive) in respect of these two requirements. From the results it is seen that, low 
PLGA concentration is beneficial for obtaining smaller NPs (see Part I) whereas it is just 
disadvantageous in respect of the encapsulation efficiency. Other variables may help to 
achieve both requirements at the same time, and there are variables which influence only 
one of them: e.g. magnetite/PLGA ratio and sonication time have significant influence on 
the mean particle size exclusively, but do not have significant effects on encapsulation 
efficiency (from Eqn. 2, XFe3O4 has coefficient of -0.0075 which is quite low) whereas 
HSA concentration influences only the encapsulation efficiency, not the mean particle 
size.  
Fig. 63b shows that for given mean particle sizes quite different encapsulation 
efficiencies can be achieved by varying the process conditions, which offers good 
opportunity for optimization of the process. To elucidate the best conditions to obtain 
suitably small NPs and high encapsulation efficiency at the same time, mathematical 
optimization was carried out by GAMSTM/MINOS software package, using the 
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descriptive model equations: Eqn.1 in Part I and Eqn.2 in Part II, referring to the 
achievable mean particle size and encapsulation efficiency as a function of process 
variables, respectively. The reason behind the optimization was to find out suitable 
conditions (process variables) to get maximum encapsulation efficiency with a constraint 
of obtaining various (allowable) mean particle sizes. Because the required magnetic 
properties of the model drug loaded NPs may be different and will be influenced by the 
relative amount of Fe3O4 nanoparticles applied in the organic phase, the optimization has 
been carried out at various magnetite/PLGA ratio. The results are shown on the 
composed diagrams in Fig. 47. 
In the bottom diagram in Fig. 47, the combined effect of PLGA concentration and 
magnetite/PLGA mass ratio is shown on the achievable mean particle size with maximal 
encapsulation efficiency (upper diagram), at fixed (optimal) values of the other three 
process variables. Among them, maximal sonication time (Xtime=3.0 min) was chosen, 
because it was the most beneficial to get the smallest achievable mean particle size, but 
had no significant direct effect on the encapsulation efficiency. The concentration of 
HSA practically had no influence on the mean particle size, but its smallest studied value, 
XHSA=0.737% (wt/vol) offered the highest encapsulation efficiency, especially at the 
smallest studied volume ratio of XVOLR=2.0 (vol/vol) (see Fig. 2(d)5). The latter volume 
ratio was the best selection to obtain the smallest mean particle size (see Part I).  
According to the lower diagram, two independent variables, i.e. PLGA 
concentration and Fe3O4/PLGA ratio determine the achievable mean particle size at fixed 
values of the other three variables. An example is shown by dotted lines for 
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XPLGA=1.83% (wt/vol) and XFe3O4=4.0% (wt/wt), resulting in a mean diameter of about 
155 nm (crossing point of the dotted lines). In the lower diagram it is also obvious that 
increasing the PLGA concentration at constant magnetite/PLGA ratio increases the mean 
particle diameter, and vice versa. Similarly, at constant PLGA concentration, the increase 
of magnetite/PLGA ratio enhances particle size and vice versa. 
Fig. 47. 
If we follow the vertical line upward to the upper diagram at a given Fe3O4:PLGA 
ratio (in Fig. 47, we hav  taken the example of XFe3O4=4.0% wt/wt), it is seen that 
arriving at the point on the curve referring to the same mean particle size (155 nm in this 
case) will give EEHSA=92.3% which is the highest encapsulation efficiency achieved 
under these conditions (Fig.47, the horizontal dotted line of the upper diagram). We can 
conclude that if HSA-loaded nanoparticles of 155 nm mean size should be produced 
(with given magnetite content determined by the Fe3O4/PLGA ratio), under optimal 
conditions as high as 92.3% encapsulation efficiency can be achieved. If smaller particles 
should be produced by using lower PLGA concentration (the crossing point of the dotted 
lines in the lower diagram of Fig. 47, that will be shifted downwards e.g. to the curve of 
145 nm), the expectable encapsulation efficiency will be decreased to about 84% (the 
ordinate value in the upper diagram where the vertical dotted line crosses the curve of 
145 nm mean size). It means the general opinion widely accepted in the literature is 
clearly confirmed: the larger is the particle size, the higher is the expected encapsulation 
efficiency and vice versa, if certain parameters such as the drug/polymer ratio in the 
emulsion are kept constant (at their optimal value). 
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In addition to the particle size and encapsulation efficiency, several other 
requirements may be also important during producing PLGA nanoparticles loaded with 
protein type drug and magnetic NPs. Such requirements can be e.g. the concentration of 
active ingredient in the nanocapsules, and/or the productivity of the applied process or 
equipment (product yield mass per unit volume of equipment and unit time). Economical 
aspects, such as the cost of production per unit mass of product can be very important 
too. However, in this study we have dealt only with the requirements of particle size and 
encapsulation efficiency as optimization criteria, also taking the magnetite/polymer ratio 
into consideration, which may be important to achieve suitable levels of magnetic 
properties of the produced nanoparticles (examination of the latter will be the subject of a 
separate study). 
Another aspect can be the concentration of the encapsulated HSA in the composite 
nanoparticles. It was also determined from the available experimental data according to 
Eqn. 3a-b, where concentration of HSA was changing from about 1.5 to 18.3% (wt/wt) 
depending on the applied process variables (Fig. 58). Considering these scattered values, 
the actual protein concentration encapsulated into the particles was primarily determined 
by the mass ratio of the introduced HSA and PLGA (both of them could be varied 
independently) and the encapsulation efficiency, influenced by the studied process 
variables. Fig. 58 also shows the increasing tendency of HSA concentration in particles 
with increasing HSA/PLGA mass ratio. It is also seen that the scattering of data also 
grows in this direction, mainly due to the increasing effect of other process variables on 
encapsulation efficiency. 
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Fig. 85. 
In Part I, it was seen that HSA concentration in the inner aqueous phase had no 
significant influence on particle size. Therefore suitably small particles can be produced 
at relatively high HSA/PLGA mass ratio, if the PLGA concentration is not too high. 
However, at the same time, increasing HSA/PLGA ratio may have detrimental effect on 
the encapsulation efficiency (see Fig. 2(a)) resulting in relatively high amount of non 
encapsulated protein in the mother solution, remaining there after solidification and 
separation of the model drug loaded NPs, which may increase the loss of the valuable 
ingredient. Fig. 2(d)5 shows that applying low volume ratio of the external aqueous and 
intermediate organic phases (XVOLR=2.0 vol/vol) which is optimal for obtaining small 
particles, the achievable encapsulation efficiency steeply decreases from 98.2 to 72.7% 
with the increase of HSA concentration at fixed other variables. This, especially for 
expensive drug ingredients may extremely deteriorate the economy of the process. 
Therefore, the optimization of protein content in the particles will also be the subject of a 
separate study. 
As an example, considering the conditions suitable for a high encapsulation 
efficiency of EEHSA=92.3%, shown by the dotted line in the upper diagram on Fig. 47, the 
achievable HSA content can be calculated which is about 3.6% (according to Eqn. 3). If 
higher protein content is needed in the particles, higher HSA/PLGA ratio should be 
applied which will diminish the efficiency of HSA encapsulation and thus leads to an 
increase in protein loss.  
CONCLUSION 
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In this study we investigated the encapsulation efficiency of model drug HSA and 
magnetite loaded PLGA NPs. In Part I, the optimum conditions for small PLGA NPs 
were proposed and in this Part II, optimum conditions for NPs of given size with highest 
possible encapsulation efficiencies are proposed. For extremely expensive active 
ingredients, high encapsulation efficiency is of the highest importance. From economic 
point of view, if encapsulation efficiency is not high, the product cost will be very high or 
may extremely destroy the economy of the process. After performing all the 81 
experiments suggested by DOE along with 9 repetitions, it was found that encapsulation 
efficiencies can be obtained from as low as 18% to as high as 97% depending on process 
conditions. However, large particles are detected and eliminated by macrophages easily 
and on the other hand, their sterilization after production is also difficult. Thus, it is 
indispensable to find out optimum conditions for the formulation of relatively small NPs 
with highest possible encapsulation efficiencies. Due to the high number of variables, it 
was necessary to determine the optimum process conditions mathematically which was 
done successfully by using GAMS™/MINOS Large Scale Nonlinear Solver software. It 
was found that for 155 nm PLGA NPs, 92.3% encapsulation efficiency can be obtained 
which is sufficiently high. But if, there is constraint in respect of magnetite/PLGA ratio, 
i.e. higher iron oxide concentration is desired in PLGA NPs to achieve sufficient level of 
saturation magnetisation, the minimum achievable mean particle size increases but, in the 
worst case, it approximately remains below 160 nm even using a magnetite/PLGA ratio 
as high as 10.0% wt/wt (Part I). From Fig. 47, it is clear that if the size is even 165 nm, 
84% model drug will be encapsulated. 
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NOMENCLATURE 
Variables 
EEHSA Encapsulation efficiency of HSA, % (Eqn.1 and Eqn.2) 
EEFe3O4 Encapsulation efficiency of magnetite nanoparticles, % (Eqn.3a,b)  
mFe3O4int Total mass of the introduced magnetite noparticles, gram 
mFe3O4encaps Mass of magnetite encapsulated into PLGA NPs, gram 
mHSAint Total mass of the introduced HSA, gram  
mHSAencaps Mass of HSA encapsulated into the particles, gram  
mPLGA Mass of PLGA introduced, gram 
VHSA Volume of the introduced HSA solution (internal phase W1), mL 
VPLGA Volume of the introduced PLGA/magnetite solution (intermediate organic 
phase), mL 
VPVA Volume of the outer aqueous phase (PVA solution), mL 
XFe3O4 Relative mass of the introduced magnetite compared to the mass of 
Page 28 of 42
URL: http://mc.manuscriptcentral.com/tmnc  Email: microencapsulation@hotmail.co.uk
Journal of Microencapsulation
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review Only
 29
PLGA, % (wt/wt) 
XPLGA Concentration of PLGA in the intermediate oily phase 
XHSA Concentration of HSA in the inner aqueous phase, % (wt/vol)  
XVOLR Volume ratio of the outer aqueous phase to the intermediate oily phase, 
vol/vol  
Xtime Time of the second sonication, min 
Other notations and indices 
O Oily phase (intermediate phase) of the emulsion 
W (W1, W2) Aqueous phase (first and second i.e. inner and external aqueous phase) 
F Result of the statistical F test on the studied variable (in ANOVA table) 
p Statistical significance level (in ANOVA table) 
df Degree of freedom (in ANOVA table) 
MS Mean square of the residuals, nm2 (in ANOVA table) 
SS Sum of deviation squares, nm2 (in ANOVA table) 
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Legends of Figures 
Fig. 1. Pareto chart on the standardized effects of the independent process variables on 
the encapsulation efficiency 
Fig. 2. The effect of various process variables on the encapsulation efficiency; fixed 
parameters: (a) PLGA and HSA concentration (b) PLGA concentration and the magnetite 
ratio to the mass of PLGA (c) interaction of the PLGA concentration and the volume 
ratio of the external and intermediate phases (d) interaction of the HSA concentration and 
the volume ratio of the external and intermediate phases.on the encapsulation efficiency  
Fig. 3. The effect of the PLGA concentration and the magnetite ratio to the mass of 
PLGA on the encapsulation efficiency  
Fig. 4. The interaction of the PLGA concentration and the volume ratio of the external 
and intermediate phases 
Fig. 5. The interaction of the HSA concentration and the volume ratio of the external and 
intermediate phases  
Fig. 63. Experimental data on the relation between the mean particle size, duration of 
second sonication and encapsulation efficiency, a - obtained mean particle size vs. 
sonication time without separation of the particular effects of different process variables, 
b – measured encapsulation efficiencies vs. measured mean particle sizes 
Fig. 74. Results of optimization at different magnetite/PLGA ratio. At optimal values of 
other process variables, PLGA concentration and magnetite/PLGA ratio determines the 
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achievable smallest mean particle size (lower diagram) and the highest encapsulation 
efficiency (upper diagram)   
Fig. 58. Experimental data on the concentration of encapsulated HSA within the 
composite PLGA-magnetite particles at different mass ratios of HSA and PLGA 
introduced into the W/O/W double emulsion  
 
 
Legends of Tables 
Table 1: ANOVA table obtained by statistical analysis of the measured encapsulation 
efficiencies obtained with different combinations of the influencing factors  
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Fig. 1. Pareto chart on the standardized effects of the independent process variables on the encapsulation 
efficiency  
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Fig. 2. The effect of various process variables on the encapsulation efficiency; fixed parameters: (a) PLGA 
and HSA concentration (b) PLGA concentration and the magnetite ratio to the mass of PLGA (c) interaction 
of the PLGA concentration and the volume ratio of the external and intermediate phases (d) interaction of 
the HSA concentration and the volume ratio of the external and intermediate phases  
828x624mm (96 x 96 DPI)  
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Fig. 3. Experimental data on the relation between the mean particle size, duration of second sonication and 
encapsulation efficiency, a - obtained mean particle size vs. sonication time without separation of the 
particular effects of different process variables, b – measured encapsulation efficiencies vs. measured mean 
particle sizes  
200x274mm (96 x 96 DPI)  
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Fig. 4. Results of optimization at different magnetite/PLGA ratio. At optimal values of other process 
variables, PLGA concentration and magnetite/PLGA ratio determines the achievable smallest mean particle 
size (lower diagram) and the highest encapsulation efficiency (upper diagram)    
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Fig. 5. Experimental data on the concentration of encapsulated HSA within the composite PLGA-magnetite 
particles at different mass ratios of HSA and PLGA introduced into the W/O/W double emulsion  
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Table 1: ANOVA table obtained by statistical analysis of the measured encapsulation 
efficiencies obtained with different combinations of the influencing factors.  
 
 
Factor 
ANOVA; Dependent Variable: Encapsulation efficiency (HSA 
EE%), 5 3-level factors, 90 Runs; MS Residual=84.425 
SS df MS F p 
F1 Fe3O4 conc. (Q) 734.44 1 734.436 8.69928 0.004147 
F2 PLGA conc. (L+Q) 12025.95 2 6012.976 71.22274 0.000000 
F3 HSA conc. (L) 3918.52 1 3918.519 46.41423 0.000000 
Interaction F2*F3 2909.34 1 2909.344 34.46071 0.000000 
Interaction F2*F4 558.06 1 558.062 6.61015 0.011946 
Interaction F3*F4 456.04 1 456.036 5.40167 0.022592 
Error 6922.85 82 84.425   
Total SS 27943.57 89    
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